APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI In Drug Development

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global AI In Drug Development Market Analysis and Forecast 2026-2032

16 April 2026215 pages

Choose your research edition.

Industry ResearchAI In Drug Development Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal AI In Drug Development Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal AI In Drug Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI In Drug Development Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal AI In Drug Development Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global AI In Drug Development market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for AI In Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for AI In Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for AI In Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for AI In Drug Development is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of AI In Drug Development include Pfizer, AstraZeneca, Johnson & Johnson, Novartis, Sanofi, Roche, Insilico Medicine, Exscientia and BenevolentAI, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for AI In Drug Development, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of AI In Drug Development, also provides the revenue of main regions and countries. Of the upcoming market potential for AI In Drug Development, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the AI In Drug Development revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global AI In Drug Development market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for AI In Drug Development revenue, projected growth trends, production technology, application and end-user industry.

AI In Drug Development Segment by Company

Pfizer

AstraZeneca

Johnson & Johnson

Novartis

Sanofi

Roche

Insilico Medicine

Exscientia

BenevolentAI

Recursion Pharmaceuticals

Atomwise

Isomorphic Labs

XtalPi

Deep Genomics

Relay Therapeutics

AI In Drug Development Segment by Type

Software

Services

AI In Drug Development Segment by Application

Biopharmaceuticals

Synthetic Pharmaceuticals

Others

AI In Drug Development Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI In Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI In Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI In Drug Development.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of AI In Drug Development in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of AI In Drug Development company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AI In Drug Development revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global AI In Drug Development Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Software Major Player Table 3. Services Major Player Table 4. Global AI In Drug Development Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Biopharmaceuticals Major Player Table 6. Synthetic Pharmaceuticals Major Player Table 7. Others Major Player Table 8. AI In Drug Development Industry Trends Table 9. AI In Drug Development Industry Drivers Table 10. AI In Drug Development Industry Opportunities and Challenges Table 11. AI In Drug Development Industry Restraints Table 12. Global AI In Drug Development Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global AI In Drug Development Market Size by Region (2021-2026) & (US$ Million) Table 14. Global AI In Drug Development Market Share by Region (2021-2026) Table 15. Global AI In Drug Development Market Size by Region (2027-2032) & (US$ Million) Table 16. Global AI In Drug Development Market Share by Region (2027-2032) Table 17. Global AI In Drug Development Revenue by Players (US$ Million) & (2021-2026) Table 18. Global AI In Drug Development Revenue Market Share by Players (2021-2026) Table 19. Global AI In Drug Development Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global AI In Drug Development Key Players Headquarters & Area Served Table 21. Global AI In Drug Development Players, Product Type & Application Table 22. Global AI In Drug Development Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global AI In Drug Development by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global AI In Drug Development Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global AI In Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 27. Global AI In Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 28. Global AI In Drug Development Revenue Market Share by Type (2021-2026) Table 29. Global AI In Drug Development Revenue Market Share by Type (2027-2032) Table 30. Global AI In Drug Development Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global AI In Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 32. Global AI In Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 33. Global AI In Drug Development Revenue Market Share by Application (2021-2026) Table 34. Global AI In Drug Development Revenue Market Share by Application (2027-2032) Table 35. Pfizer Company Information Table 36. Pfizer Business Overview Table 37. Pfizer AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Pfizer AI In Drug Development Product Portfolio Table 39. Pfizer Recent Development Table 40. AstraZeneca Company Information Table 41. AstraZeneca Business Overview Table 42. AstraZeneca AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. AstraZeneca AI In Drug Development Product Portfolio Table 44. AstraZeneca Recent Development Table 45. Johnson & Johnson Company Information Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Johnson & Johnson AI In Drug Development Product Portfolio Table 49. Johnson & Johnson Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novartis AI In Drug Development Product Portfolio Table 54. Novartis Recent Development Table 55. Sanofi Company Information Table 56. Sanofi Business Overview Table 57. Sanofi AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Sanofi AI In Drug Development Product Portfolio Table 59. Sanofi Recent Development Table 60. Roche Company Information Table 61. Roche Business Overview Table 62. Roche AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Roche AI In Drug Development Product Portfolio Table 64. Roche Recent Development Table 65. Insilico Medicine Company Information Table 66. Insilico Medicine Business Overview Table 67. Insilico Medicine AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Insilico Medicine AI In Drug Development Product Portfolio Table 69. Insilico Medicine Recent Development Table 70. Exscientia Company Information Table 71. Exscientia Business Overview Table 72. Exscientia AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Exscientia AI In Drug Development Product Portfolio Table 74. Exscientia Recent Development Table 75. BenevolentAI Company Information Table 76. BenevolentAI Business Overview Table 77. BenevolentAI AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. BenevolentAI AI In Drug Development Product Portfolio Table 79. BenevolentAI Recent Development Table 80. Recursion Pharmaceuticals Company Information Table 81. Recursion Pharmaceuticals Business Overview Table 82. Recursion Pharmaceuticals AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Recursion Pharmaceuticals AI In Drug Development Product Portfolio Table 84. Recursion Pharmaceuticals Recent Development Table 85. Atomwise Company Information Table 86. Atomwise Business Overview Table 87. Atomwise AI In Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Atomwise AI In Drug Development Product Portfolio Table 89. Atomwise Recent Development Table 90. Isomorphic Labs Company Information Table 91. Isomorphic Labs Business Overview Table 92. Isomorphic Labs AI In Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Isomorphic Labs AI In Drug Development Product Portfolio Table 94. Isomorphic Labs Recent Development Table 95. XtalPi Company Information Table 96. XtalPi Business Overview Table 97. XtalPi AI In Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. XtalPi AI In Drug Development Product Portfolio Table 99. XtalPi Recent Development Table 100. Deep Genomics Company Information Table 101. Deep Genomics Business Overview Table 102. Deep Genomics AI In Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Deep Genomics AI In Drug Development Product Portfolio Table 104. Deep Genomics Recent Development Table 105. Relay Therapeutics Company Information Table 106. Relay Therapeutics Business Overview Table 107. Relay Therapeutics AI In Drug Development Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Relay Therapeutics AI In Drug Development Product Portfolio Table 109. Relay Therapeutics Recent Development Table 110. North America AI In Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 111. North America AI In Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 112. North America AI In Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 113. North America AI In Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 114. North America AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America AI In Drug Development Revenue by Country (2021-2026) & (US$ Million) Table 116. North America AI In Drug Development Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe AI In Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe AI In Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe AI In Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe AI In Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe AI In Drug Development Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe AI In Drug Development Revenue by Country (US$ Million) & (2027-2032) Table 124. China AI In Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 125. China AI In Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 126. China AI In Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 127. China AI In Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia AI In Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia AI In Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia AI In Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia AI In Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia AI In Drug Development Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia AI In Drug Development Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia AI In Drug Development Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA AI In Drug Development Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA AI In Drug Development Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA AI In Drug Development Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA AI In Drug Development Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA AI In Drug Development Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA AI In Drug Development Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. AI In Drug Development Image Figure 2. Global AI In Drug Development Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI In Drug Development Market Size Share 2021 VS 2025 VS 2032 Figure 4. Software Image Figure 5. Services Image Figure 6. Global AI In Drug Development Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global AI In Drug Development Market Size Share 2021 VS 2025 VS 2032 Figure 8. Biopharmaceuticals Image Figure 9. Synthetic Pharmaceuticals Image Figure 10. Others Image Figure 11. Global AI In Drug Development Market Size (US$ Million) & (2021-2032) Figure 12. Global AI In Drug Development Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global AI In Drug Development Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global AI In Drug Development Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global AI In Drug Development Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global AI In Drug Development Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global AI In Drug Development Revenue Market Share by Type (2021-2032) Figure 19. Global AI In Drug Development Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global AI In Drug Development Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global AI In Drug Development Revenue Market Share by Application (2021-2032) Figure 22. North America AI In Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America AI In Drug Development Revenue Share by Type (2021-2032) Figure 24. North America AI In Drug Development Revenue Share by Application (2021-2032) Figure 25. North America AI In Drug Development Revenue Share by Country (2021-2032) Figure 26. United States AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe AI In Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe AI In Drug Development Revenue Share by Type (2021-2032) Figure 31. Europe AI In Drug Development Revenue Share by Application (2021-2032) Figure 32. Europe AI In Drug Development Revenue Share by Country (2021-2032) Figure 33. Germany AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China AI In Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China AI In Drug Development Revenue Share by Type (2021-2032) Figure 43. China AI In Drug Development Revenue Share by Application (2021-2032) Figure 44. Asia AI In Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia AI In Drug Development Revenue Share by Type (2021-2032) Figure 46. Asia AI In Drug Development Revenue Share by Application (2021-2032) Figure 47. Asia AI In Drug Development Revenue Share by Region (2021-2032) Figure 48. Japan AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA AI In Drug Development Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA AI In Drug Development Revenue Share by Type (2021-2032) Figure 56. SAMEA AI In Drug Development Revenue Share by Application (2021-2032) Figure 57. SAMEA AI In Drug Development Revenue Share by Country (2021-2032) Figure 58. Brazil AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt AI In Drug Development Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Software
  • Services
Applications
  • Biopharmaceuticals
  • Synthetic Pharmaceuticals
  • Others
Companies covered
  • Pfizer
  • AstraZeneca
  • Johnson & Johnson
  • Novartis
  • Sanofi
  • Roche
  • Insilico Medicine
  • Exscientia
  • BenevolentAI
  • Recursion Pharmaceuticals
  • Atomwise
  • Isomorphic Labs
  • XtalPi
  • Deep Genomics
  • Relay Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 AI In Drug Development Market by Type
  3. 1.2.1 Global AI In Drug Development Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Software
  5. 1.2.3 Services
  6. 1.3 AI In Drug Development Market by Application
  7. 1.3.1 Global AI In Drug Development Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Biopharmaceuticals
  9. 1.3.3 Synthetic Pharmaceuticals
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 AI In Drug Development Market Dynamics
  1. 2.1 AI In Drug Development Industry Trends
  2. 2.2 AI In Drug Development Industry Drivers
  3. 2.3 AI In Drug Development Industry Opportunities and Challenges
  4. 2.4 AI In Drug Development Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global AI In Drug Development Market Perspective (2021-2032)
  2. 3.2 Global AI In Drug Development Growth Trends by Region
  3. 3.2.1 Global AI In Drug Development Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global AI In Drug Development Market Size by Region (2021-2026)
  5. 3.2.3 Global AI In Drug Development Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global AI In Drug Development Revenue by Players
  2. 4.1.1 Global AI In Drug Development Revenue by Players (2021-2026)
  3. 4.1.2 Global AI In Drug Development Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global AI In Drug Development Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global AI In Drug Development Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global AI In Drug Development Key Players Headquarters & Area Served
  7. 4.4 Global AI In Drug Development Players, Product Type & Application
  8. 4.5 Global AI In Drug Development Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global AI In Drug Development Market CR5 and HHI
  11. 4.6.3 2025 AI In Drug Development Tier 1, Tier 2, and Tier 3
5 AI In Drug Development Market Size by Type
  1. 5.1 Global AI In Drug Development Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global AI In Drug Development Revenue by Type (2021-2032)
  3. 5.3 Global AI In Drug Development Revenue Market Share by Type (2021-2032)
6 AI In Drug Development Market Size by Application
  1. 6.1 Global AI In Drug Development Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global AI In Drug Development Revenue by Application (2021-2032)
  3. 6.3 Global AI In Drug Development Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer AI In Drug Development Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer AI In Drug Development Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 AstraZeneca
  8. 7.2.1 AstraZeneca Company Information
  9. 7.2.2 AstraZeneca Business Overview
  10. 7.2.3 AstraZeneca AI In Drug Development Revenue and Gross Margin (2021-2026)
  11. 7.2.4 AstraZeneca AI In Drug Development Product Portfolio
  12. 7.2.5 AstraZeneca Recent Developments
  13. 7.3 Johnson & Johnson
  14. 7.3.1 Johnson & Johnson Company Information
  15. 7.3.2 Johnson & Johnson Business Overview
  16. 7.3.3 Johnson & Johnson AI In Drug Development Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson AI In Drug Development Product Portfolio
  18. 7.3.5 Johnson & Johnson Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis AI In Drug Development Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis AI In Drug Development Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi AI In Drug Development Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi AI In Drug Development Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche AI In Drug Development Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche AI In Drug Development Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Insilico Medicine
  38. 7.7.1 Insilico Medicine Company Information
  39. 7.7.2 Insilico Medicine Business Overview
  40. 7.7.3 Insilico Medicine AI In Drug Development Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Insilico Medicine AI In Drug Development Product Portfolio
  42. 7.7.5 Insilico Medicine Recent Developments
  43. 7.8 Exscientia
  44. 7.8.1 Exscientia Company Information
  45. 7.8.2 Exscientia Business Overview
  46. 7.8.3 Exscientia AI In Drug Development Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Exscientia AI In Drug Development Product Portfolio
  48. 7.8.5 Exscientia Recent Developments
  49. 7.9 BenevolentAI
  50. 7.9.1 BenevolentAI Company Information
  51. 7.9.2 BenevolentAI Business Overview
  52. 7.9.3 BenevolentAI AI In Drug Development Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BenevolentAI AI In Drug Development Product Portfolio
  54. 7.9.5 BenevolentAI Recent Developments
  55. 7.10 Recursion Pharmaceuticals
  56. 7.10.1 Recursion Pharmaceuticals Company Information
  57. 7.10.2 Recursion Pharmaceuticals Business Overview
  58. 7.10.3 Recursion Pharmaceuticals AI In Drug Development Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Recursion Pharmaceuticals AI In Drug Development Product Portfolio
  60. 7.10.5 Recursion Pharmaceuticals Recent Developments
  61. 7.11 Atomwise
  62. 7.11.1 Atomwise Company Information
  63. 7.11.2 Atomwise Business Overview
  64. 7.11.3 Atomwise AI In Drug Development Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Atomwise AI In Drug Development Product Portfolio
  66. 7.11.5 Atomwise Recent Developments
  67. 7.12 Isomorphic Labs
  68. 7.12.1 Isomorphic Labs Company Information
  69. 7.12.2 Isomorphic Labs Business Overview
  70. 7.12.3 Isomorphic Labs AI In Drug Development Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Isomorphic Labs AI In Drug Development Product Portfolio
  72. 7.12.5 Isomorphic Labs Recent Developments
  73. 7.13 XtalPi
  74. 7.13.1 XtalPi Company Information
  75. 7.13.2 XtalPi Business Overview
  76. 7.13.3 XtalPi AI In Drug Development Revenue and Gross Margin (2021-2026)
  77. 7.13.4 XtalPi AI In Drug Development Product Portfolio
  78. 7.13.5 XtalPi Recent Developments
  79. 7.14 Deep Genomics
  80. 7.14.1 Deep Genomics Company Information
  81. 7.14.2 Deep Genomics Business Overview
  82. 7.14.3 Deep Genomics AI In Drug Development Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Deep Genomics AI In Drug Development Product Portfolio
  84. 7.14.5 Deep Genomics Recent Developments
  85. 7.15 Relay Therapeutics
  86. 7.15.1 Relay Therapeutics Company Information
  87. 7.15.2 Relay Therapeutics Business Overview
  88. 7.15.3 Relay Therapeutics AI In Drug Development Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Relay Therapeutics AI In Drug Development Product Portfolio
  90. 7.15.5 Relay Therapeutics Recent Developments
8 North America
  1. 8.1 North America AI In Drug Development Revenue (2021-2032)
  2. 8.2 North America AI In Drug Development Revenue by Type (2021-2032)
  3. 8.2.1 North America AI In Drug Development Revenue by Type (2021-2026)
  4. 8.2.2 North America AI In Drug Development Revenue by Type (2027-2032)
  5. 8.3 North America AI In Drug Development Revenue Share by Type (2021-2032)
  6. 8.4 North America AI In Drug Development Revenue by Application (2021-2032)
  7. 8.4.1 North America AI In Drug Development Revenue by Application (2021-2026)
  8. 8.4.2 North America AI In Drug Development Revenue by Application (2027-2032)
  9. 8.5 North America AI In Drug Development Revenue Share by Application (2021-2032)
  10. 8.6 North America AI In Drug Development Revenue by Country
  11. 8.6.1 North America AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America AI In Drug Development Revenue by Country (2021-2026)
  13. 8.6.3 North America AI In Drug Development Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe AI In Drug Development Revenue (2021-2032)
  2. 9.2 Europe AI In Drug Development Revenue by Type (2021-2032)
  3. 9.2.1 Europe AI In Drug Development Revenue by Type (2021-2026)
  4. 9.2.2 Europe AI In Drug Development Revenue by Type (2027-2032)
  5. 9.3 Europe AI In Drug Development Revenue Share by Type (2021-2032)
  6. 9.4 Europe AI In Drug Development Revenue by Application (2021-2032)
  7. 9.4.1 Europe AI In Drug Development Revenue by Application (2021-2026)
  8. 9.4.2 Europe AI In Drug Development Revenue by Application (2027-2032)
  9. 9.5 Europe AI In Drug Development Revenue Share by Application (2021-2032)
  10. 9.6 Europe AI In Drug Development Revenue by Country
  11. 9.6.1 Europe AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe AI In Drug Development Revenue by Country (2021-2026)
  13. 9.6.3 Europe AI In Drug Development Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China AI In Drug Development Revenue (2021-2032)
  2. 10.2 China AI In Drug Development Revenue by Type (2021-2032)
  3. 10.2.1 China AI In Drug Development Revenue by Type (2021-2026)
  4. 10.2.2 China AI In Drug Development Revenue by Type (2027-2032)
  5. 10.3 China AI In Drug Development Revenue Share by Type (2021-2032)
  6. 10.4 China AI In Drug Development Revenue by Application (2021-2032)
  7. 10.4.1 China AI In Drug Development Revenue by Application (2021-2026)
  8. 10.4.2 China AI In Drug Development Revenue by Application (2027-2032)
  9. 10.5 China AI In Drug Development Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia AI In Drug Development Revenue (2021-2032)
  2. 11.2 Asia AI In Drug Development Revenue by Type (2021-2032)
  3. 11.2.1 Asia AI In Drug Development Revenue by Type (2021-2026)
  4. 11.2.2 Asia AI In Drug Development Revenue by Type (2027-2032)
  5. 11.3 Asia AI In Drug Development Revenue Share by Type (2021-2032)
  6. 11.4 Asia AI In Drug Development Revenue by Application (2021-2032)
  7. 11.4.1 Asia AI In Drug Development Revenue by Application (2021-2026)
  8. 11.4.2 Asia AI In Drug Development Revenue by Application (2027-2032)
  9. 11.5 Asia AI In Drug Development Revenue Share by Application (2021-2032)
  10. 11.6 Asia AI In Drug Development Revenue by Country
  11. 11.6.1 Asia AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia AI In Drug Development Revenue by Country (2021-2026)
  13. 11.6.3 Asia AI In Drug Development Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA AI In Drug Development Revenue (2021-2032)
  2. 12.2 SAMEA AI In Drug Development Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA AI In Drug Development Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA AI In Drug Development Revenue by Type (2027-2032)
  5. 12.3 SAMEA AI In Drug Development Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA AI In Drug Development Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA AI In Drug Development Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA AI In Drug Development Revenue by Application (2027-2032)
  9. 12.5 SAMEA AI In Drug Development Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA AI In Drug Development Revenue by Country
  11. 12.6.1 SAMEA AI In Drug Development Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA AI In Drug Development Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA AI In Drug Development Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst